The customer reported false reactive hiv ag/ab results for various samples that were repeat reactive, when processing on the architect i2000sr.The following information was provided: sid: (b)(4): initial result was 2.10 s/co and retest was 3.48 s/co for an (b)(6) year old male, pre-operative patient.Additional testing for this patient was immunoblot negative.Fifteen days after the hiv result, the patient was treated with immunoglobulin and a tomography was performed.This patient past medical history includes idiopathic thrombocytopenic purpura and he currently has a platelet count of 10000 platelets.Due to the low number of platelets the procedure was not performed.No additional impact to patient management was reported.
|
Adverse event or product problem: updated to product problem from adverse event.Event: updated to include: additional information regarding the patient was provided.The patient was treated with immunoglobulin due to idiopathic thrombocytopenia and not due to the abbott false reactive hiv result.Additionally, the tomography was performed due to the patients gastric symptoms and the patient was not operated on due to the low platelet count.An investigation was performed for the customer issue and included a review of the complaint text, a search for similar complaints, a review of tracking and trending data, a review of the performance of the likely cause, testing using a retained reagent kit of the complaint lot, and a review of product labeling.Ticket searches determined that there is slightly elevated complaint activity for the likely cause lots, but most complaints were for false reactive results.The tracking and trending report did not identify any trends for the complaint issue.Worldwide field data was used to review the overall performance of architect hiv ag/ab combo reagents and determined the values for the complaint lot are within their established limits and comparable to the values of other architect hiv ag/ab combo reagent lot numbers.The field data showed that reagent performance regarding specificity is acceptable.A retained reagent kit of the complaint lot was tested in a specificity setup.Results of this setup did not implicate that the specificity performance of the lot is negatively impacted.The reagent kit showed normal performance without false reactive results.No nonconformances, potential non-conformances or deviations were identified.A systemic issue was not identified.Labeling was reviewed and found to be adequate.Based on all available information and abbott diagnostics' complaint investigation a product deficiency was not identified.A second patient event is being submitted against the same suspect medical device, in manufacturer report number 3002809144-2019-00352.
|